Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore

News

Stay up to date on the latest crypto trends with our expert, in-depth coverage.

banner
All
Crypto
Stocks
Commodities & Forex
Macro
Flash
01:05
Solana founder: It’s difficult for the Foundation to “force” ecosystem growth, there needs to be products first before promotion can be done
According to Odaily, Solana founder toly stated this morning when discussing the role of the Solana Foundation in ecosystem development: "Someone has to launch a product first, then the Foundation can promote and publicize it. People provide feedback, test it, let the team know what doesn't work, and then the team improves it." "It's difficult for the Foundation to force anything... Even when providing grants or investments, there has to be a product first and people willing to use it; only then can the ecosystem accelerate its development."
01:01
The total net inflow of SOL spot ETF in the United States reached $3.7829 million in a single day.
Odaily reported, according to SoSoValue data, on May 19 (Eastern US time), SOL spot ETFs saw a total net inflow of 3.7829 million USD in a single day. The SOL spot ETF with the highest net inflow yesterday was Fidelity Solana Fund ETF (FSOL), with a single-day net inflow of 3.2227 million USD, and its historical total net inflow has reached 178 million USD. The second highest was VanEck Solana ETF (VSOL), with a single-day net inflow of 560.2 thousand USD, and its historical total net inflow has reached 18.2476 million USD. As of the time of publication, the total net asset value of SOL spot ETFs is 958 million USD, the net asset ratio of SOL is 1.96%, and the cumulative historical net inflow has reached 1.121 billion USD.
00:56
ImmunityBio, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Anktiva® (nogapendekin alfa inbakicept) in combination with BCG for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary disease.
The FDA has also set the Prescription Drug User Fee Act (PDUFA) target date for this application—January 6, 2027. This sBLA submission is based on positive data from a pivotal phase 2/3 clinical trial. The study evaluated the efficacy and safety of Anktiva in combination with BCG in BCG-unresponsive NMIBC patients. Data show that this combination therapy significantly improved the complete response rate and demonstrated good tolerability. If approved, Anktiva combined with BCG will provide an important new treatment option for this patient population with limited therapeutic choices. The PDUFA date marks the FDA’s target timeline for completing its review, but the final decision may come before or after this date.
News